Chiron Issues Fourth Quarter, Full-Year Earnings Restatement
This article was originally published in The Pink Sheet Daily
Executive Summary
The restatement is the result of improper revenue recognition of traveler vaccines in the second quarter and later periods, Chiron says. The company also reports lower flu vaccine sales as part of the restatement.